New first-in-human study explores immune-engineered cell therapy approach for type 1 diabetes

Researchers have launched a first-in-human study to test if immune-engineered, insulin-producing cells can function in type 1 diabetes patients without the need for chronic immunosuppression. This approach aims to overcome the primary barrier of immune rejection in cell replacement therapies.